|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 318.55 EUR | +0.25% |
|
-2.54% | +13.65% |
| 08/07 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 08/07 | Morgan Stanley Adjusts Price Target Amgen to $333 From $340, Maintains Equalweight Rating | MT |
| Market Cap | 20TCr 17TCr 16TCr 15TCr 28TCr 18,70500Cr 28TCr 1,89100Cr 74TCr 9,21500Cr 74TCr 72TCr 31,67800Cr | P/E 2026 * |
23.8x | P/E 2027 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise Value | 24TCr 21TCr 19TCr 18TCr 34TCr 22,72000Cr 34TCr 2,29600Cr 90TCr 11,19300Cr 89TCr 87TCr 38,47800Cr | EV / Sales 2026 * |
6.31x | EV / Sales 2027 * | 6.01x |
| Free-Float |
99.78% | Yield 2026 * |
2.78% | Yield 2027 * | 2.93% |
Last Transcript: Amgen Inc.
| 1 day | +0.25% | ||
| 1 week | -2.54% | ||
| Current month | +1.30% | ||
| 1 month | +4.96% | ||
| 3 months | +6.09% | ||
| 6 months | +12.64% | ||
| Current year | +13.65% |
| 1 week | 316 |  | 327.65 |
| 1 month | 291.7 | | 327.65 |
| Current year | 271.8 | | 333 |
| 1 year | 230 | | 333 |
| 3 years | 200.8 | | 333 |
| 5 years | 174.58 | | 333 |
| 10 years | 120.65 | | 333 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
| Director of Finance/CFO | 62 | 13/05/2010 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | -2.54% | - | - | 20TCr | |
| -2.33% | -2.09% | +49.88% | +170.51% | 1,06000Cr | |
| -0.82% | -2.30% | +63.79% | +62.00% | 62TCr | |
| -0.73% | -4.98% | +28.91% | +82.99% | 44TCr | |
| +0.33% | -1.17% | +31.07% | +27.09% | 33TCr | |
| -0.02% | -2.85% | +29.15% | +45.24% | 28TCr | |
| -3.89% | -11.22% | +22.81% | +27.30% | 27TCr | |
| +0.66% | -1.42% | -26.59% | -37.71% | 22TCr | |
| -3.72% | -1.10% | +18.41% | +70.56% | 16TCr | |
| -0.33% | -0.62% | -5.77% | -32.90% | 14TCr | |
| Average | -1.06% | -2.99% | +23.52% | +46.12% | 39.06TCr | |
| Weighted average by Cap. | -1.26% | -2.87% | +35.85% | +80.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.78TCr 3.3TCr 3.05TCr 2.81TCr 5.34TCr 3,60200Cr 5.43TCr 36TCr 14TCr 1,77400Cr 14TCr 14TCr 6,10000Cr | 3.87TCr 3.38TCr 3.12TCr 2.88TCr 5.47TCr 3,69000Cr 5.56TCr 37TCr 15TCr 1,81800Cr 15TCr 14TCr 6,24900Cr |
| Net income | 823.05Cr 719.92Cr 664.04Cr 613.3Cr 1.16TCr 78TCr 1.18TCr 7.93TCr 3.12TCr 39TCr 3.09TCr 3.02TCr 1,32900Cr | 885.95Cr 774.94Cr 714.79Cr 660.18Cr 1.25TCr 84TCr 1.27TCr 8.54TCr 3.35TCr 42TCr 3.33TCr 3.25TCr 1,43100Cr |
| Net Debt | 4.21TCr 3.68TCr 3.4TCr 3.14TCr 5.95TCr 4,01500Cr 6.05TCr 41TCr 16TCr 1,97800Cr 16TCr 15TCr 6,80000Cr | 3.66TCr 3.2TCr 2.95TCr 2.72TCr 5.17TCr 3,48600Cr 5.26TCr 35TCr 14TCr 1,71700Cr 14TCr 13TCr 5,90400Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | €318.55 | +0.25% | 92 |
| 09/26/09 | €317.75 | -1.61% | 283 |
| 08/26/08 | €322.95 | +0.19% | 711 |
| 07/26/07 | €322.35 | +1.32% | 209 |
| 06/26/06 | €318.15 | -2.66% | 295 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMG Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
